<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>3839</number>
    <updateDate>2024-07-24T15:21:45Z</updateDate>
    <updateDateIncludingText>2024-07-24T15:21:45Z</updateDateIncludingText>
    <originChamber>House</originChamber>
    <originChamberCode>H</originChamberCode>
    <type>HR</type>
    <introducedDate>2023-06-06</introducedDate>
    <congress>118</congress>
    <constitutionalAuthorityStatementText><![CDATA[<pre>[Congressional Record Volume 169, Number 98 (Tuesday, June 6, 2023)][House]From the Congressional Record Online through the Government Publishing Office [<a href="https://www.gpo.gov">www.gpo.gov</a>]By Mr. DUNN of Florida:H.R. 3839.Congress has the power to enact this legislation pursuantto the following:Article I, Section 8, clause 3 provides Congress with thepower ``to regulate commerce with foreign nations, and amongthe several states, and with the Indian tribes.''The single subject of this legislation is:This bill alters the FDA review process for complex genericdrug applications.[Page H2763]</pre>]]></constitutionalAuthorityStatementText>
    <committees>
      <item>
        <systemCode>hsif00</systemCode>
        <name>Energy and Commerce Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <subcommittees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
            <activities>
              <item>
                <name>Referred to</name>
                <date>2023-06-09T18:17:34Z</date>
              </item>
            </activities>
          </item>
        </subcommittees>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2023-06-06T14:01:25Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>PATIENT Act of 2023</title>
        <congress>118</congress>
        <number>3561</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2023-05-24</actionDate>
          <text>Ordered to be Reported (Amended) by the Yeas and Nays: 49 - 0.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Increasing Transparency in Generic Drug Applications Act</title>
        <congress>118</congress>
        <number>775</number>
        <type>S</type>
        <latestAction>
          <actionDate>2023-03-14</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Expanding Access to Low-Cost Generics Act of 2023</title>
        <congress>118</congress>
        <number>1114</number>
        <type>S</type>
        <latestAction>
          <actionDate>2023-06-22</actionDate>
          <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 108.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Lower Costs, More Transparency Act</title>
        <congress>118</congress>
        <number>5378</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2023-12-11</actionDate>
          <text>Motion to reconsider laid on the table Agreed to without objection.</text>
          <actionTime>19:13:20</actionTime>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2023-06-09</actionDate>
        <committees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2023-06-06</actionDate>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2023-06-06</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2023-06-06</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>D000628</bioguideId>
        <fullName>Rep. Dunn, Neal P. [R-FL-2]</fullName>
        <firstName>Neal</firstName>
        <lastName>Dunn</lastName>
        <party>R</party>
        <state>FL</state>
        <middleName>P.</middleName>
        <district>2</district>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>K000382</bioguideId>
        <fullName>Rep. Kuster, Ann M. [D-NH-2]</fullName>
        <firstName>Ann</firstName>
        <lastName>Kuster</lastName>
        <party>D</party>
        <state>NH</state>
        <middleName>M.</middleName>
        <district>2</district>
        <sponsorshipDate>2023-06-06</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Administrative law and regulatory procedures</name>
          <updateDate>2023-10-11T19:30:24Z</updateDate>
        </item>
        <item>
          <name>Department of Health and Human Services</name>
          <updateDate>2023-10-11T19:30:24Z</updateDate>
        </item>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
          <updateDate>2023-10-11T19:30:24Z</updateDate>
        </item>
        <item>
          <name>Prescription drugs</name>
          <updateDate>2023-10-11T19:30:24Z</updateDate>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
        <updateDate>2023-07-06T19:30:24Z</updateDate>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2023-06-06</actionDate>
        <actionDesc>Introduced in House</actionDesc>
        <updateDate>2023-10-03T15:46:31Z</updateDate>
        <text><![CDATA[ <p></p> <p>This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.</p>]]></text>
      </summary>
    </summaries>
    <title>To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <titleTypeCode>45</titleTypeCode>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.</title>
        <updateDate>2024-07-24T15:21:45Z</updateDate>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <titleTypeCode>6</titleTypeCode>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.</title>
        <updateDate>2024-03-18T20:57:11Z</updateDate>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in House</type>
        <date>2023-06-06T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-118hr3839ih/xml/BILLS-118hr3839ih.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2023-06-09</actionDate>
      <text>Referred to the Subcommittee on Health.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
